Ariceum Therapeutics

Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd

by

Acquisition of next generation radiopharmaceutical clinical pipeline to include Auger-based systemic targeted PARP inhibitor radiation therapies Expansion of operations in the US Acquisition of commercial FDA-approved, diagnostic product NEPHROSCANTM in partnership with GE Healthcare and Ga-68 kit technology IP currently licensed to Novartis Theragnostics’ and Ariceum’s leadership teams to join forces creating a specialist team … Read more

UCB and Ariceum Therapeutics sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer

by

UCB’s expertise in macrocyclic peptide discovery, using its proprietary mRNA-display platform, ExtremeDiversity™, will aid Ariceum’s discovery of treatments for solid tumors Ariceum’s expertise in radiopharmaceuticals and labelling technology will aid UCB’s discovery of treatments for immune-related diseases Potential to expand Ariceum’s pipeline with three new programs at discovery stage BERLIN and BRUSSELS, May 11, 2023 … Read more